571.45
+0.12(+0.02%)
Currency In USD
| Previous Close | 571.33 |
| Open | 572.38 |
| Day High | 577.21 |
| Day Low | 561.05 |
| 52-Week High | 605 |
| 52-Week Low | 265 |
| Volume | 137,493 |
| Average Volume | 343,847 |
| Market Cap | 12.67B |
| PE | -44.26 |
| EPS | -12.91 |
| Moving Average 50 Days | 494.18 |
| Moving Average 200 Days | 376.04 |
| Change | 0.12 |
If you invested $1000 in Madrigal Pharmaceuticals, Inc. (MDGL) 10 years ago, it would be worth $52,668.2 as of December 14, 2025 at a share price of $571.45. Whereas If you bought $1000 worth of Madrigal Pharmaceuticals, Inc. (MDGL) shares 5 years ago, it would be worth $4,733.29 as of December 14, 2025 at a share price of $571.45.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
GlobeNewswire Inc.
Nov 17, 2025 1:00 PM GMT
CONSHOHOCKEN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences: Jefferies Global Healthcare Conference in
Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis
GlobeNewswire Inc.
Nov 10, 2025 1:00 PM GMT
Rezdiffra® treatment significantly improved liver stiffness, fibrosis biomarkers, and markers of clinically significant portal hypertension risk in patients with compensated MASH cirrhosis Rezdiffra also improved disease-specific quality of life meas
Madrigal to Present New Data from the Company’s MASH Program at AASLD’s The Liver Meeting 2025
GlobeNewswire Inc.
Oct 28, 2025 12:00 PM GMT
Two oral presentations to highlight biomarker, imaging and quality-of-life data from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of RezdiffraPoster of distinction examines the impact of Rezdiffra interrupt